(PDF) Population Pharmacokinetics of Subcutaneous and

Population Pharmacokinetics of Subcutaneous and Intradermal Glucagon in Patients With Type 1 Diabetes

Clinical Therapeutics - United States

doi 10.1016/j.clinthera.2015.05.052

Full Text

Abstract

Available in full text

Categories

Date

August 1, 2015

Authors

M.G. Spigarelli

Publisher

Elsevier BV

Related search

Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Combination With Insulin in Japanese Patients With Type 1 Diabetes

Diabetes, Obesity and Metabolism

Internal Medicine

English

Effects of Subcutaneous Glucagon-Like Peptide 1 (GLP-1 [7-36 Amide]) in Patients With NIDDM

Internal Medicine

English

Inappropriate Glucagon Response After Oral Compared With Isoglycemic Intravenous Glucose Administration in Patients With Type 1 Diabetes

American Journal of Physiology - Endocrinology and Metabolism

English

Vitiligo Associated With Subcutaneous Insulin Lispro Infusion in Type 1 Diabetes

Internal Medicine

Specialized Nursing

English

Response to “Preserved” Glucagon Secretion in Fulminant Type 1 Diabetes

Journal of Diabetes Investigation

Internal Medicine

English

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Advances in Therapy

English

Consequences of Delayed Pump Infusion Line Change in Patients With Type 1 Diabetes Mellitus Treated With Continuous Subcutaneous Insulin Infusion

Journal of Diabetes and its Complications

Internal Medicine

English

Hypoglycaemia Unawareness in Patients With Type 1 Diabetes

Pediatric Endocrinology, Diabetes and Metabolism

English

Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat

Pharmaceutical Science

English